Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study).
Casas Deza D, Julián Gomara AB, Caudevilla Biota E, Beltrán B, Domènech E, Gutiérrez Casbas A, Mañosa M, Zabana Y, Roc Alfaro L, Valverde Romero E, García González E, Sicilia B, Laredo V, Alcalá Escriche MJ, Madero Velázquez L, Ferreiro-Iglesias R, Palmero Pérez A, Calafat M, Rubio Iturria S, Moraleja Yudego I, Ber Nieto Y, García Mateo S, P Gisbert J, Vicente Lidón R, Arias L, Alfambra E, Doñate Borao AB, Peña González E, Corsino Roche P, Vicuña Arregui M, Elorza A, Domínguez Cajal M, Chaparro M, Barreiro-de Acosta M, García-López S. Casas Deza D, et al. Among authors: vicente lidon r. Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00474-0. doi: 10.1016/j.gastrohep.2023.11.004. Online ahead of print. Gastroenterol Hepatol. 2023. PMID: 38007154 English, Spanish.
HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.
Pascual-Oliver A, Casas-Deza D, Cuarán C, García-López S, Corsino-Roche P, Sierra-Moros E, Olier-Martínez P, González-Tarancón R, Vicente-Lidón R. Pascual-Oliver A, et al. Among authors: vicente lidon r. Inflamm Bowel Dis. 2023 Jul 18:izad130. doi: 10.1093/ibd/izad130. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37462462
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.
Chaparro M, Acosta D, Rodríguez C, Mesonero F, Vicuña M, Barreiro-de Acosta M, Fernández-Clotet A, Hernández Martínez Á, Arroyo M, Vera I, Ruiz-Cerulla A, Sicilia B, Cabello Tapia MJ, Muñoz Villafranca C, Castro-Poceiro J, Martínez Cadilla J, Sierra-Ausín M, Vázquez Morón JM, Vicente Lidón R, Bermejo F, Royo V, Calafat M, González-Muñoza C, Leo Carnerero E, Manceñido Marcos N, Torrealba L, Alonso-Galán H, Benítez JM, Ber Nieto Y, Diz-Lois Palomares MT, García MJ, Muñoz JF, Armesto González EM, Calvet X, Hernández-Camba A, Madrigal Domínguez RE, Menchén L, Pérez Calle JL, Piqueras M, Dueñas Sadornil C, Botella B, Martínez-Pérez TJ, Ramos L, Rodríguez-Grau MC, San Miguel E, Fernández Forcelledo JL, Fradejas Salazar PM, García-Sepulcre M, Gutiérrez A, Llaó J, Sesé Abizanda E, Boscá-Watts M, Iyo E, Keco-Huerga A, Martínez Bonil C, Peña González E, Pérez-Galindo P, Varela P, Gisbert JP; To-ReWard Study Group. Chaparro M, et al. Among authors: vicente lidon r. Am J Gastroenterol. 2023 Jul 1;118(7):1237-1247. doi: 10.14309/ajg.0000000000002145. Epub 2022 Dec 14. Am J Gastroenterol. 2023. PMID: 36716287
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient's perspective: IBD-Control, EII-Control.
Vicente Lidón R, García López S, Corsino Roche P, Boudet Barraca JM, Sanz Segura P, García Cámara P, Sierra Moros E, Gomollón García F. Vicente Lidón R, et al. Gastroenterol Hepatol. 2022 Aug-Sep;45(7):524-534. doi: 10.1016/j.gastrohep.2021.08.001. Epub 2021 Aug 21. Gastroenterol Hepatol. 2022. PMID: 34428475 English, Spanish.
Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
Casas Deza D, García López S, Lafuente Blasco M, Vicente Lidón R, Nerín de la Puerta J, Peña Gonzalez E, Ber Nieto Y, Charro Calvillo M, Alcalá Escriche MJ, Gomollón García F, Arroyo Villarino M. Casas Deza D, et al. Among authors: vicente lidon r. Gastroenterol Hepatol. 2020 Mar;43(3):126-132. doi: 10.1016/j.gastrohep.2019.09.011. Epub 2019 Dec 19. Gastroenterol Hepatol. 2020. PMID: 31866167 English, Spanish.